key: cord-0685219-f075txcd
authors: Ramirez, Angie L.; Luna, Nicolas; Patiño, Luz H.; Castañeda, Sergio; Muñoz, Marina; Ballesteros, Nathalia; Perez, Julie; Correa‐Cárdenas, Camilo A.; Duque, Maria Clara; Mendez, Claudia; Oliveros, Carolina; Paniz‐Mondolfi, Alberto E.; Ramírez, Juan David
title: Impact of SARS‐CoV‐2 Mu variant on vaccine effectiveness: A comparative genomics study at the peak of the third wave in Bogota, Colombia
date: 2022-05-03
journal: J Med Virol
DOI: 10.1002/jmv.27808
sha: 47db6051524f723ef8c9b63a1e6eee1782c7b0b5
doc_id: 685219
cord_uid: f075txcd

We assessed the circulation of severe acute respiratory syndrome coronavirus‐2 variants amongst vaccinated military personnel in Bogotá, Colombia to evaluate the mutations of certain variants and their potential for breakthrough infection in vaccinated subjects. We observed that in vaccinated individuals the most frequent infecting lineage was Mu (B.1.621 and B.1.621.1). The above is possibly associated with specific mutations that confer it with vaccine‐induced immune escape ability. Our findings highlight the importance of how genomic tracking coupled with epidemiological surveillance can assist in the study of novel emerging variants (e.g., Omicron) and their impact on vaccination efforts worldwide.

After the first reports of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-associated pneumonia in Wuhan, China, in 2019 the coronavirus disease (COVID-19) has spread globally, causing over five million deaths worldwide. 1 Colombia ranks fourth as the country with the highest number of COVID-19-related deaths in Latin America, only preceded by Brazil, Mexico, and Peru. 2 To overcome the effects of the pandemic, a number of vaccine alternatives have been implemented, including traditional live attenuated/killed virus vaccines, viral vectored, and recombinant/ peptide vaccines, as well as more novel approaches such as messenger RNA (mRNA)-based vaccines. 3 Nevertheless, the everevolving nature of the virus has led to the emergence of variants with changing mutational landscapes conferring the ability to evade neutralizing antibodies and possibly compromise current vaccine effectiveness. 4 Most countries throughout the world have concentrated efforts on achieving herd immunity by maintaining steadily increasing vaccination rates. In Latin America, as of December 2021, estimates indicate that about half of the population has completed vaccination schemes. 5 

We sequenced 57 nasopharyngeal swabs taken during the third epidemiological wave (between May and August 2021) from COVID-

Nanopore. Nanopore sequencing has been broadly used as a reliable system to support the current COVID-19 pandemic due to its ability to generate long reads and rapid sequencing for an effective public health response. 9 The vaccination status of the patients corre- 

The monitoring of variants with immune evasion capacity is essential in evaluating the effectiveness of vaccination against these variants of the virus and as a strategy to tackle this pandemic. Our results showed that in vaccinated individuals, the most frequent infecting variant was Mu, probably associated with its vaccine-induced immune escape ability. 10 Mutations in the spike protein such as T19R, L452R, T478K, D614G, and P681R (present in VOCs as delta)

have been linked to the potential reduction in vaccine efficacy. 8 which has shown to be less effective for neutralizing variants harboring mutations in the spike such as P681H (present in Mu). 12 Although Pfizer has shown higher efficacy (95%) in preventing symptomatic disease than Sinovac (~50.65%), results may vary between regions as a reflection of the impact of new variants. 13, 14 For example, a study carried out by Serrano-Coll et al. 15 

The authors declare no conflicts of interest.

The data that support the findings of this study are available in the Supporting Information Material of this article.

COVID-19 coronavirus pandemic

COVID-19) en América Latina y el Caribe al 2 de diciembre de

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

SARS-CoV-2 variants, spike mutations and immune escape

COVID-19) en América Latina y el Caribe a 2 de diciembre de

Efectividad de las vacunas contra el COVID-19 en Colombia

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review

Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding

Bezmin Abadi AT. The Mu strain: the last but not least circulating 'variant of interest' potentially affecting the COVID-19 pandemic

Emergence of lineage B. 1.621 in Latin America and the Caribbean

Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant

Sinovac says COVID-19 vaccine effective in preventing hospitalization, death. Reuters

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Effectiveness of the CoronaVac ® vaccine in a region of the Colombian Amazon, was herd immunity achieved?

Characterization of the emerging B. 1.621 variant of interest of SARS-CoV-2. medRxiv

Does the world need an Omicron vaccine? What researchers say

SARS-CoV-2 variants detected in the UK. UK Health Security Agency

Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: a comparative genomics study at the peak of the third wave in Bogota, Colombia